A scaffold, not an implant
GalaFLEX is often described to patients as 'mesh', which is accurate but incomplete. It is a thin, flexible, knitted sheet of a single polymer fibre — poly-4-hydroxybutyrate, P4HB — produced by fermentation rather than from animal or human tissue. Sewn into the breast, it does two things in sequence. For the first months it works as a physical support: the manufacturer's preclinical data put strength retention at roughly half of the original at twelve weeks, which covers the period in which a surgical repair is weakest. Meanwhile the body grows collagen through its pores, and as the polymer is absorbed — essentially completely within 18–24 months — that collagen layer is what remains. The scaffold is MR-safe and contains no metal.
Where it earns its place in revision
Revision breast surgery is largely a fight against stretched or thin tissue, and that is where a temporary support is logical. The common uses: reinforcing a rebuilt inframammary fold after bottoming out; backing a lateral capsulorrhaphy when implants drift towards the armpit; supporting the midline closure in symmastia; holding a new fold after double bubble correction; acting as a lower-pole sling — the so-called internal bra — when a lift is performed over implants; and supporting a revision mastopexy that has dropped once already. The common thread is a repair the surgeon expects the patient's own tissue to struggle to hold on its own.
What it does not do
A scaffold does not correct a pocket that was dissected in the wrong place; it reinforces a pocket the surgeon has already corrected with sutures. It does not compensate for an implant that is too heavy for the tissue — downsizing does that, and the two are usually combined. It does not treat capsular contracture by itself, and whether it lowers recurrence is the question a trial is currently asking. It does not make implants last longer than they otherwise would, and it does not remove the need for the band, garment and movement rules that protect every pocket repair. In thin patients it can be felt as a firm edge for some months. Anyone presenting it as a guarantee is overselling a useful tool.
Regulatory status, in plain words
In the United States GalaFLEX is cleared as a general soft-tissue reinforcement scaffold for plastic and reconstructive surgery; its label states it has not been studied in breast reconstruction. In November 2023 the FDA wrote to clinicians that no surgical mesh is cleared or approved specifically for breast surgery and that the agency has not determined safety and effectiveness in that setting — and, in the same letter, that it does not recommend removing scaffolds from patients who have no symptoms. In Europe, and therefore in Türkiye, the product carries a CE mark as a soft-tissue support scaffold. A randomized, controlled trial of GalaFLEX LITE in breast revision (the STANCE study) has been enrolling since 2025; by August 2026 it had treated 274 patients and reached its first interim analysis, with no results yet published. Until that changes, breast use is a surgeon's judgment call made with the patient's informed consent — which is how Dr. Erdal frames it.
The evidence so far
The longest published series is a single-surgeon review of 248 patients treated with P4HB in aesthetic breast surgery between 2012 and 2022, with a mean follow-up of 2.9 years (Sinclair and Adams, Aesthetic Surgery Journal, 2024). Breast ptosis was the most common indication; the overall complication rate was 8.0 percent, the unplanned reoperation rate 2.8 percent, and patient satisfaction remained stable over time. Smaller mastopexy series report the lower pole holding its position better at one year than skin-only lifts usually do. The honest reading: encouraging, consistent, and still mostly retrospective. Randomized data are coming; they are not here yet.
How the decision is made in the clinic
The scaffold is considered, not assumed: when tissue is thin or lax, when a previous repair has failed, when the implant is heavy relative to the breast, when a lift is planned over implants, or when the patient's history (large weight change, pregnancies, earlier pocket problems) predicts a repair that will be tested. The alternatives — suture-only repair, an acellular dermal matrix, downsizing, staging — are compared openly in this guide. Consent covers the off-label status, the risks, and the fact that the scaffold's details are recorded on your implant record for any future surgeon. Photographs and your implant card through the assessment are enough to say whether a scaffold belongs in your plan at all.
Frequently Asked Questions
What is GalaFLEX made of, and does it stay in the body?
GalaFLEX is a knitted monofilament scaffold made of poly-4-hydroxybutyrate (P4HB), a biologically derived polymer. It is gradually absorbed — the manufacturer states resorption is essentially complete in 18–24 months — and is replaced by a layer of the patient's own collagen. Nothing permanent remains.
Is GalaFLEX approved for breast surgery?
It is cleared in the United States and CE-marked in Europe as a soft-tissue reinforcement scaffold for plastic and reconstructive surgery. No mesh or scaffold has a specific clearance for breast augmentation or revision; the FDA said so in a 2023 letter, and a randomized trial of GalaFLEX LITE in breast revision is still running. Its use in the breast is therefore a surgeon's clinical judgment, made with explicit informed consent.
Does GalaFLEX prevent capsular contracture?
That has not been established. A randomized trial is testing exactly this question. What the scaffold does reliably is mechanical: it reinforces a repaired fold, pocket wall or lower pole while the repair heals. Contracture is treated by capsulectomy, pocket change and a new implant — not by a scaffold alone.